A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514

ABSTRACT Background Nab‐sirolimus (ABI‐009, nab‐rapamycin; Aadi Bioscience Inc. [Aadi]) is a human albumin‐bound form of sirolimus nanoparticles, a potent mTOR inhibitor. This phase I trial was conducted to define dose‐limiting toxicities (DLT), maximum tolerated or recommended phase II dose (MTD/RP...

Description complète

Détails bibliographiques

Auteurs principaux:	Stuart L. Cramer, Alyssa Terry Reddy, Charles Gene Minard, Stephan Voss, Elizabeth Fox, Xiaowei Liu, Kristina Denic, Joel M. Reid, Brenda J. Weigel
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2024-11-01
Collection:	Cancer Medicine
Sujets:	ABI‐009 Clinical trial nab‐rapamycin Pediatrics rapamycin
Accès en ligne:	https://doi.org/10.1002/cam4.70376
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!